Dr. Ed Baker

Dr. Baker trained received his medical training at Loma Linda University.  After completing his specialty training in Obstetrics and Gynecology, he practiced in the San Francisco bay area as a community physician for nearly 10 years.  

In 2002 he became interested in drug development and took a position with Organon Pharmaceuticals, a company focused on Women’s health, where he ultimately became the head of the global Medical Affairs team for women’s health.  He has been involved in the development and registration of dozens of products for women’s health and often lectures and writes on a variety of topics related to women’s health.  Prior to his current position he was head of Medical Affairs at Actelion Pharmaceuticals, a company that focused its efforts on rare diseases.  

He was attracted to his current position at Roche Molecular diagnostics because it presents a great opportunity to help shift a longstanding paradigm in cervical cancer screening.  In addition to his work with Roche's cervical cancer prevention portfolio he is also responsible for developmental projects in genetics and oncology and has a keen interest in the area of companion diagnostics.

Dr. Baker maintains his OB/GYN board certification and holds an appointment as Associate Professor of Medicine in the OB/GYN department at UC Davis.

This blog is part of the Early Diagnosis campaign #BeFirst Early diagnosis and care can prevent illness from developing and slow disease progression. Lab tests, genetic tests, tests for chronic diseases and modern lab diagnostics can help facilitate earlier intervention and improves outcomes for patients and are increasingly valuable in informing treatment choice. Read the other blogs here: A smarter way to fight colorectal cancer , Can screening decrease lung cancer mortality rates? , Kidney Disease: catch it early to save lives and money , For kidney disease patients, treatment education and choice are key to better outcomes , Diagnosing severe hearing loss and deafness **************************************** The impact of cervical cancer can be reduced by timely detection of the viruses that cause it. Early detection of cancer-causing human papillomaviruses (HPV) allows prompt intervention, sparing women the trauma of disease – and saving lives. Cervical cancer strikes women in the prime of their lives. The median age for diagnosis is 49 – when people are likely to be active in work and family life – but the virus that causes the disease may have been present for decades before cancer was detected. One in 100 women in Europe will develop cervical cancer in their lifetime. In addition to anxiety and pain, the disease can severe reproductive health issues and, in some cases, premature death. 14 types of human papillomaviruses are known to cause the disease. HPV 16 and HPV 18 are the highest risk types, accounting for more than 70% of cases. HPV is a very common virus, transmitted by skin-to-skin contact. There’s no shame in carrying the virus – most people have it at some point in their lives. In fact, close to 80% of all sexually active adults will get HPV. The good news is that the virus often...